Medpace (MEDP)
(Delayed Data from NSDQ)
$333.45 USD
-0.35 (-0.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $334.83 +1.38 (0.41%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$333.45 USD
-0.35 (-0.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $334.83 +1.38 (0.41%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum A VGM
Zacks News
Zacks.com featured highlights Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom
by Zacks Equity Research
Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom have been highlighted in this Screen of The Week article.
3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)
by Zacks Equity Research
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
QIAGEN (QGEN) to Enhance Forensics With New Partnership
by Zacks Equity Research
QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.
Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised
by Zacks Equity Research
Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.
5 Stocks With Upgraded Broker Ratings Worth Investing in Now
by Swayta Shah
Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Medpace (MEDP), American Axle & Manufacturing (AXL), Diebold Nixdorf (DBD), Euronet (EEFT) and Omnicom (OMC).
Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.
Are Medical Stocks Lagging Medpace (MEDP) This Year?
by Zacks Equity Research
Here is how Medpace (MEDP) and Tenet Healthcare (THC) have performed compared to their sector so far this year.
STERIS (STE) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.
Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
by Zacks Equity Research
Charles River's (CRL) Manufacturing and RMS business segments report organic revenue growth.
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.
Here's Why Investors Should Retain Labcorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Labcorp (LH), led by strategic acquisitions and strong expansion in the Biopharma Laboratory.
Medpace Holdings, Inc. (MEDP) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Medpace (MEDP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
by Zacks Equity Research
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.
Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
5 Growth Stocks to Buy for Steady Returns in May
by Nalak Das
We have narrowed our search to five growth stocks that have solid upside left for 2024. These stocks are NFLX, WING, PATH, SKX and MEDP.
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
by Zacks Equity Research
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.
Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.
Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.
Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y
by Zacks Equity Research
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
by Zacks Equity Research
Illumina (ILMN) surpasses expectations in the first quarter in a challenging global macroeconomic environment.
Tandem Diabetes (TNDM) Posts Narrower Q1 Loss, Raises '24 View
by Zacks Equity Research
Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
Brokers Suggest Investing in Medpace (MEDP): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Medpace (MEDP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
by Zacks Equity Research
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.